Mountain Group Capital

Mountain Group News

Latest News

Applied LifeSciences & Systems Announces Closing of its $8 Million Series A Round of Equity Financing

Raleigh, NC — March 20, 2019 — Applied LifeSciences & Systems (ALSS) announced today the close of an $8 million Series A round of equity financing. The financing was co-led by Merck Animal Health (MAH), through its newly formed Merck Animal Health Ventures Group, and Mountain Group Partners (MGP). ALSS integrates its proprietary technologies in high speed imaging, feature recognition, artificial intelligence, robotics & microfluidics in a system that can…

Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

Study results are consistent with previously published prospective and retrospective studies

FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of patients with Stage IB and II cutaneous melanoma showing that the DecisionDx®-Melanoma gene expression profile (GEP) test accurately identifies risk of melanoma recurrence. The study was published in the Journal of the European Academy of Dermatology and Venereology. Results are consistent with the…

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced the publication of a study highlighting the ability of the DecisionDx®-Melanoma test to accurately determine risk of metastasis in patients with melanoma of the head and neck. Results from the study demonstrated that the DecisionDx-Melanoma test can provide independent information about recurrence risk in patients with tumors of…

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

Validation data from 1,421 patients published in Future Oncology

FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions for use of sentinel lymph node biopsy (SLNB), a surgical procedure used to help stage melanoma. The study found that the DecisionDx-Melanoma test result can be used with clinicopathologic factors to inform patient discussions and…

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

Results from this cumulative validation study are consistent with prior multicenter and single-center, independent prospective studies

FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced a new publication demonstrating that the DecisionDx®-Melanoma gene expression profile (GEP) test can identify high-risk patients who are likely to recur or die from melanoma within groups of patients often considered low risk based on traditional staging metrics. Results from this multicenter study of 690 patients demonstrated that the…

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors

Friendswood, Texas – December 6, 2018 – Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors. Mr. Cole brings over 30 years of successful finance and operations leadership in the diagnostics and life sciences industries. Currently he is Chief Financial Officer of Genomic Health, a leading provider of genomic-based diagnostic…

Silicon Ranch to Help Power Facebook Data Center in Georgia

MONROE, Ga., Dec. 5, 2018 /PRNewswire—Walton Electric Membership Corporation (EMC), a consumer-owned utility with a reputation for energy innovation, has executed contracts with two solar developers for three new solar projects as part of its agreement to supply 100 percent renewable energy for Facebook’s data center in Newton County, Georgia. The collaboration is the largest solar development project in Georgia. Facebook chose Walton EMC as the power supplier for the Newton Data Center when…

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

Palmetto GBA issues final local coverage determination effective December 3, 2018

Friendswood, Texas – Oct 18, 2018 – Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma. “Improved access to the DecisionDx-Melanoma test for the 59 million Medicare recipients can drive better-informed management decisions…

PhaseBio Secures $34 Million in Series D Financing

Proceeds will advance clinical development of orphan disease therapies, expand application of ELP technology platform

Malvern, PA, August 27, 2018 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the completion of a $34 million Series D financing, including the conversion of existing convertible promissory notes. New investors in the financing include Rock Springs Capital, Mountain Group Partners and CormorantAsset Management. Existing investors New Enterprise…

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

Test demonstrated high technical reliability in over 17,000 clinical orders

Friendswood, TX – July 30, 2018 – Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of new data showing that the DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging. The study was presented at the DERM2018 NP/PA CME Conference held in Las Vegas, Nevada. The study assessed the impact on…

Next Page →